|
DeNardo, Gerald L; DeNardo, Sally J; Peterson, James J et al. (2003) Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates. Clin Cancer Res 9:3865S-72S
|
|
Burke, Patricia A; DeNardo, Sally J; Miers, Laird A et al. (2002) Combined modality radioimmunotherapy. Promise and peril. Cancer 94:1320-31
|
|
DeNardo, G L; Kroger, L A; Meares, C F et al. (1998) Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts. Clin Cancer Res 4:2483-90
|
|
DeNardo, S J; Kroger, L A; Lamborn, K R et al. (1997) Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer 80:2583-90
|
|
Winthrop, M D; DeNardo, S J; Muenzer, J T et al. (1997) p53-independent response of a human breast carcinoma xenograft to radioimmunotherapy. Cancer 80:2529-37
|
|
Richman, C M; Schuermann, T C; Wun, T et al. (1997) Peripheral blood stem cell mobilization for hematopoietic support of radioimmunotherapy in patients with breast carcinoma. Cancer 80:2728-32
|
|
Howell, L P; DeNardo, S J; Levy, N B et al. (1995) Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: A comparative study. Int J Biol Markers 10:129-35
|
